Kaiser Permanente to Evaluate Neopath's AutoPap 300 QC System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

REDMOND, Wash--NeoPath Inc has signed an agreement with Kaiser Permanente to install AutoPap 300 QC Systems at its Northern California facility. Following a successful evaluation, Kaiser Permanente anticipates making the technology available to its nearly 2.5 million Northern California members.

REDMOND, Wash--NeoPath Inc has signed an agreement with KaiserPermanente to install AutoPap 300 QC Systems at its Northern Californiafacility. Following a successful evaluation, Kaiser Permanenteanticipates making the technology available to its nearly 2.5million Northern California members.

The AutoPap System rescreens Pap smear slides initially classifiedas normal, using high-speed image processing computers, videoimaging technology, and image interpretation software. In clinicaltrials in US laboratories, the system improved the detection rateof false-negative smears.

Recent Videos
3 experts in this video
3 experts in this video
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
3 experts in this video
3 experts in this video
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
Related Content